Position in XENE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$795,363
+$281,783 QoQ
Shares Held
13,177
+49.2% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
#188
of 309 holders
Holding Since
Mar 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in XENE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026EntryPoint Capital, LLC holds $21,800,288 across 60 Biotechnology names. XENE ranks #4 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UPB |
Upstream Bio, Inc.
|
129,446 | $895,766 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
25,766 | $860,326 | |
| 3 | AUPH |
Aurinia Pharmaceuticals Inc.
|
48,218 | $818,259 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
This page
|
13,177 | $795,363 | |
| 5 | FULC |
Fulcrum Therapeutics, Inc.
|
217,199 | $794,948 | |
| 6 | INCY |
Incyte Corp
|
6,483 | $734,912 | |
| 7 | IMCR |
Immunocore Holdings plc
|
22,815 | $724,376 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
3,574 | $669,338 |
All Filings in XENE
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $795,363 | 13,177 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $513,580 | 8,832 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $225,354 | 5,028 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $201,874 | 5,028 | Shares | Sole | 2025-11-13 | |
| 2025-03-31 | $297,655 | 8,872 | Shares | Sole | 2025-05-14 | |
| 2024-06-30 | $1,013 | 26 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $195,490 | 4,541 | Shares | Sole | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||